Recently, TYILLO, a US-originated international premium precision nutrition brand, has garnered global attention with its "Precision Preventive Medicine" strategy. Anchored by strategic partnerships with the world’s top universities and in-depth collaboration with Nobel laureates, the brand boasts over 100 international patents and a rigorous clinical validation system, redefining the scientific benchmark for nutritional supplements.

TYILLO’s research team is led by Professor Randy Schekman, the laureate of the 2013 Nobel Prize in Physiology or Medicine, who serves as the Honorary Chief Scientist. The brand has established a long-term strategic partnership with the Harvard Institute for Regenerative Medicine, assembling an interdisciplinary team covering cell biology, molecular nutrition and clinical medicine. This collaboration with the top university solidifies TYILLO’s leading position at the forefront of aging intervention, cellular repair and other cutting-edge fields.

TYILLO has independently developed more than 100 international patent technologies and built four core technology platforms. Its cardiovascular and cerebrovascular care technology is protected by an international patent (Patent No.: LU600995). Leveraging an original targeted delivery system and small-molecule absorption technology, it enables active ingredients to act precisely on diseased cells, boosting bioavailability to an impressive 98.5% and breaking through the absorption bottlenecks of traditional formulations.

Backed by a global supply chain, TYILLO has established five international production bases in the United States, Australia, New Zealand, Singapore, Japan and Hong Kong, China. All bases uniformly implement GMP standards and intelligent production processes, ensuring that all products meet the highest quality requirements of international authoritative certifications including the US FDA, cGMP, SGS and NSF.

Adhering to the principle of "No clinical validation, no market launch", TYILLO has forged in-depth collaborations with leading clinical institutions such as Massachusetts General Hospital and The Johns Hopkins Hospital, with all its products passing stringent randomized double-blind controlled clinical trials. Double-blind trials of the cardiovascular and cerebrovascular series demonstrated an 82% thrombus inhibition rate and a 41% improvement in vascular elasticity; clinical data of the targeted anti-aging series showed an average 37% increase in telomere length; and the neurocognitive series led to a 31% rise in cognitive function scores among participants. TYILLO has thus become one of the world’s few brands to achieve 100% clinical validation across its entire product portfolio.Use this text to share information about your brand with your customers. Describe a product,share announcements,or welcome customers to your store.

TYILLO’s offline channels have deepened into the core circle of global health industry, with its products selling well in more than 30 countries and regions, covering key markets in North America, Europe and the Asia-Pacific. TYILLO has become the preferred partner for numerous high-net-worth individuals and professional institutions in high-end anti-aging centers, private medical clinics and health management organizations worldwide.Use this text to share information about your brand with your customers. Describe a product,share announcements,or welcome customers to your store.

TYILLO’s offline channels have deepened into the core circle of global health industry, with its products selling well in more than 30 countries and regions, covering key markets in North America, Europe and the Asia-Pacific. TYILLO has become the preferred partner for numerous high-net-worth individuals and professional institutions in high-end anti-aging centers, private medical clinics and health management organizations worldwide.